His main research interests are in early clinical development, phase I trials across solid tumours, pharmacodynamic biomarkers, early phase II trials and sarcoma. He is also involved in translational research aspects related to sensitivity and resistance to targeted therapies, notably in soft-tissue sarcoma models.
He is a peer reviewer for several oncology journals and has contributed to over 200 peer-reviewed publications, including publications as first or last author in the Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.